Samsung Bioepis files lawsuit against AbbVie on Humira patents
Apr 4, 2016
South Korean biosimilar developer Samsung Bioepis has filed a lawsuit against the original maker of the world’s top-selling rheumatoid arthritis drug Humira (adalimumab), to make way for the market debut of its Humira biosimilar. The Samsung Group affiliate and its partner and minority shareholder Biogen filed a suit in the U.K. on Mar. 24 challenging a number of patents held by U.S. pharmaceuticals giant AbbVie on Humira. It is the U.S. firm’s top-valued drug, having generated sales of $14 bill